Abstract
1. UK-68,798, a novel class III anti-arrhythmic agent was administered intravenously to twelve healthy volunteers in a placebo controlled, double-blind, dose-escalating study. 2. Doses of 5 and 10 micrograms kg-1 of UK-68,798 selectively and significantly prolonged the QT interval, with mean maximum changes of 35 and 107 ms respectively, without affecting other ECG intervals. 3. There were dose-related increases in AUC but clearance (23 l h-1), terminal elimination half-life (8 h) and volume of distribution (245 l) were found to be independent of dose with low levels of intra- and inter-patient variability. 4. UK-68,798 has electrophysiological effects indicative of selective class III anti-arrhythmic activity and merits further assessment in clinical studies.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Campbell R. W., Gardiner P., Amos P. A., Chadwick D., Jordan R. S. Measurement of the QT interval. Eur Heart J. 1985 Nov;6 (Suppl 500):81–83. doi: 10.1093/eurheartj/6.suppl_d.81. [DOI] [PubMed] [Google Scholar]
- Cooper G., 4th, Kent R. L., Mann D. L. Load induction of cardiac hypertrophy. J Mol Cell Cardiol. 1989 Dec;21 (Suppl 5):11–30. doi: 10.1016/0022-2828(89)90768-2. [DOI] [PubMed] [Google Scholar]
- Debbas N. M., du Cailar C., Bexton R. S., Demaille J. G., Camm A. J., Puech P. The QT interval: a predictor of the plasma and myocardial concentrations of amiodarone. Br Heart J. 1984 Mar;51(3):316–320. doi: 10.1136/hrt.51.3.316. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Gillis A. M., Kates R. E. Clinical pharmacokinetics of the newer antiarrhythmic agents. Clin Pharmacokinet. 1984 Sep-Oct;9(5):375–403. doi: 10.2165/00003088-198409050-00001. [DOI] [PubMed] [Google Scholar]
- Nademanee K., Singh B. N., Hendrickson J. A., Reed A. W., Melmed S., Hershman J. Pharmacokinetic significance of serum reverse T3 levels during amiodarone treatment: a potential method for monitoring chronic drug therapy. Circulation. 1982 Jul;66(1):202–211. doi: 10.1161/01.cir.66.1.202. [DOI] [PubMed] [Google Scholar]
- Vaughan Williams E. M. Delayed ventricular repolarization as an anti-arrhythmic principle. Eur Heart J. 1985 Nov;6 (Suppl 500):145–149. doi: 10.1093/eurheartj/6.suppl_d.145. [DOI] [PubMed] [Google Scholar]
- Walker D. K., Aherne G. W., Arrowsmith J. E., Cross P. E., Kaye B., Smith D. A., Stopher D. A., Wild W. Measurement of the class III antidysrhythmic drug, UK-68,798, in plasma by radioimmunoassay. J Pharm Biomed Anal. 1991;9(2):141–149. doi: 10.1016/0731-7085(91)80137-x. [DOI] [PubMed] [Google Scholar]
- Whiting B., Holford N. H., Sheiner L. B. Quantitative analysis of the disopyramide concentration-effect relationship. Br J Clin Pharmacol. 1980 Jan;9(1):67–75. doi: 10.1111/j.1365-2125.1980.tb04799.x. [DOI] [PMC free article] [PubMed] [Google Scholar]